Lingating, Esterlita .
HRN: 06-81-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/29/2024
MUPIROCIN 2%, 15G (TUBE)
03/29/2024
04/05/2024
TOPICAL
Apply Thinly
BID
Blisters, Breast Malignancy R, S/p MRM R
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes